Nebivolol attenuates redox-sensitive glomerular and tubular mediated proteinuria in obese rats

Endocrinology

Volumn 152, Issue 2, 2011, Pages 659-668

  Habibi, Javad ^a,c   Hayden, Melvin R ^a,c   Sowers, James R ^a,b,c,d   Pulakat, Lakshmi ^a,c   Tilmon, Roger D ^a,c   Manrique, Camila ^a,c   Lastra, Guido ^a,c   DeMarco, Vincent G ^a,c   Whaley Connell, Adam ^a,b,c  

^a Diabetes and Cardiovascular Center   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c University of Missouri   (United States)

^d Department of Internal Medicine ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; GAMMA GLUTAMYLTRANSFERASE; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 2; MEGALIN; MINERALOCORTICOID RECEPTOR; NEBIVOLOL; NEPHRIN; PRORENIN RECEPTOR; SYNAPTOPODIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; INSULIN RESISTANCE; INSULIN SENSITIVITY; KIDNEY PROXIMAL TUBULE; MALE; NONHUMAN; OBESITY; OXIDATIVE STRESS; PODOCYTE; PRIORITY JOURNAL; PROTEIN URINE LEVEL; PROTEINURIA; RAT;

ANIMALS; ANTIHYPERTENSIVE AGENTS; BENZOPYRANS; ETHANOLAMINES; IMMUNOHISTOCHEMISTRY; KIDNEY; KIDNEY GLOMERULUS; KIDNEY TUBULES, PROXIMAL; MALE; MICROSCOPY, ELECTRON, TRANSMISSION; NADPH OXIDASE; OBESITY; OXIDATION-REDUCTION; PROTEINURIA; RANDOM ALLOCATION; RATS; RATS, ZUCKER; REACTIVE OXYGEN SPECIES;

EID: 79951639177     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2010-1038     Document Type: Article

References (41)

1. Hsu CY, McCulloch CE, Iribarren C, Darbinian J, Go AS 2006 Body mass index and risk for end-stage renal disease. Ann Intern Med 144:21-28 (Pubitemid 46780716)
2. Ejerblad E, Fored M, Lindblad P, Fryzek J, McLaughlin JK, Nyrén O 2006 Obesity and risk of chronic renal failure. J Am Soc Nephrol 17:1695-1702 (Pubitemid 43794672)
3. Chen J, Muntner P, Hamm LL, Fonseca V, Batuman V, Whelton PK, He J 2003 Insulin resistance and risk of chronic kidney disease in nondiabetic U.S. adults. J Am Soc Nephrol 14:469-477 (Pubitemid 36150872)
4. Sowers JR 2004 Insulin resistance and hypertension. Am J Physiol Heart Circ Physiol 286:H1597-H1602 (Pubitemid 38525443)
5. Cooper SA, Whaley-Connell A, Habibi J, Wei Y, Lastra G, Manrique C, Stas S, Sowers JR 2007 Renin-angiotensin-aldosterone system and oxidative stress in cardiovascular insulin resistance. Am J Physiol Heart Circ Physiol 293:H2009-H2023 (Pubitemid 47605846)
6. Jaimes EA, Hua P, Tian RX, Raij L 2010 Human glomerular endothelium: interplay among glucose, free fatty acids, angiotensin II, and oxidative stress. Am J Physiol Renal Physiol 298:F125-F132
7. Fujii H, Kono K, Nakai K, Goto S, Komaba H, Hamada Y, Shinohara M, Kitazawa R, Kitazawa S, Fukagawa M 2010 Oxidative and nitrosative stress and progression of diabetic nephropathy in type 2 diabetes. Am J Nephrol 31:342-352
8. Kakoki M, Hirata Y, Hayakawa H, Suzuki E, Nagata D, Nishimatsu H, Kimura K, Goto A, Omata M 2000 Effects of vasodilatory antihypertensive agents on endothelial dysfunction in rats with ischemic acute renal failure. Hypertens Res 23:527-533
9. Goh SY, Jasik M, Cooper ME 2008 Agents in development for the treatment of diabetic nephropathy. Expert Opin Emerg Drugs 13:447-463
10. Kalinowski L, Dobrucki LW, Szczepanska-Konkel M, Jankowski M, Martyniec L, Angielski S, Malinski T 2003 Third-generation beta-blockers stimulate nitric oxide release from endothelial cells through ATP efflux: a novel mechanism for antihypertensive action. Circulation 107:2747-2752 (Pubitemid 36667251)
11. Klahr S, Morrissey J 2004 L-arginine as a therapeutic tool in kidney disease. Semin Nephrol 24:389-394 (Pubitemid 38900638)
12. Georgescu A, Pluteanu F, Flonta ML, Badila E, Dorobantu M, Popov D 2005 The cellular mechanisms involved in the vasodilator effect of nebivolol on the renal artery. Eur J Pharmacol 508:159-166 (Pubitemid 40169915)
13. Pires MJ, Rodríguez-Peña AB, Arévalo M, Cenador B, Evangelista S, Esteller A, Sánchez-Rodríguez A, Colaço A, López-Novoa JM 2007 Long-term nebivolol administration reduces renal fibrosis and prevents endothelial dysfunction in rats with hypertension induced by renal mass reduction. J Hypertens 25:2486-2496 (Pubitemid 350060388)
14. O'Donnell VB, Freeman BA 2001 Interactions between nitric oxide and lipid oxidation pathways: implications for vascular disease. Circ Res 88:12-21 (Pubitemid 32064077)
15. Whaley-Connell A, Habibi J, Johnson M, Tilmon R, Rehmer N, Rehmer J, Wiedmeyer C, Ferrario CM, Sowers JR 2009 Nebivolol reduces proteinuria and renal NADPH oxidase generated reactive oxygen species in the transgenic Ren2 rat. Am J Nephrol 30:354-360
16. Hayden MR, Habibi J, Whaley-Connell A, Sowers D, Johnson M, Tilmon R, Jain D, Ferrario C, Sowers JR 2010 Nebivolol attenuates maladaptive proximal tubule remodeling in transgenic rats. Am J Nephrol 31:262-272
17. Fratta Pasini A, Garbin U, Nava MC, Stranieri C, Davoli A, Sawamura T, Lo Cascio V, Cominacini L 2005 Nebivolol decreases oxidative stress in essential hypertensive patients and increases nitric oxide by reducing its oxidative inactivation. J Hypertens 23:589-596 (Pubitemid 40684718)
18. Van de Water A, Janssens W, Van Neuten J, Xhonneux R, De Cree J, Verhaegen H, Reneman RS, Janssen PA 1988 Pharmacological and hemodynamic profile of nebivolol, a chemically novel, potent, and selective β1-adrenergic antagonist. J Cardiovasc Pharmacol 11:552-563
19. Bowman AJ, Chen CP, Ford GA 1994 Nitric oxide mediated venodilator effects of nebivolol. Br J Clin Pharmacol 38:199-204 (Pubitemid 24282739)
20. Tzemos N, Lim PO, MacDonald TM 2001 Nebivolol reverses endothelial dysfunction in essential hypertension: a randomized, double-blind, crossover study. Circulation 104:511-514 (Pubitemid 32738117)
21. Bosomworth MP, Aparicio SR, Hay AW 1999 Urine N-acetyl-β- Dglucosaminidase- a marker of tubular damage? Nephrol Dial Transplant 14:620-626
22. Jarad G, Miner JH 2009 Albuminuria, wherefore art thou? J Am Soc Nephrol 20:455-457
23. Russo LM, Sandoval RM, Campos SB, Molitoris BA, Comper WD, Brown D 2009 Impaired tubular uptake explains albuminuria in early diabetic nephropathy. J Am Soc Nephrol 20:489-494
24. Comper WD, Hilliard LM, Nikolic-Paterson DJ, Russo LM 2008 Disease-dependent mechanisms of albuminuria. Am J Physiol Renal Physiol 295:F1589-F1600
25. Coimbra TM, Janssen U, Gröne HJ, Ostendorf T, Kunter U, Schmidt H, Brabant G, Floege J 2000 Early events leading to renal injury in obese Zucker (fatty) rats with type II diabetes. Kidney Int 57:167-182 (Pubitemid 30227764)
26. Whaley-Connell A, DeMarco VG, Lastra G, Manrique C, Nistala R, Cooper SA, Westerly B, Hayden MR, Wiedmeyer C, Wei Y, Sowers JR 2008 Insulin resistance, oxidative stress, and podocyte injury; role of rosuvastatin modulation of filtration barrier injury in the Zucker obese rat. Am J Nephrol 28:67-75 (Pubitemid 350126495)
27. Zhou X, Ma L, Habibi J, Whaley-Connell A, Hayden MR, Tilmon RD, Brown AN, Kim JA, Demarco VG, Sowers JR 2010 Nebivolol improves diastolic dysfunction and myocardial remodeling through reductions in oxidative stress in the Zucker obese rat. Hypertension 55:880-888
28. Whaley-Connell AT, Chowdhury NA, Hayden MR, Stump CS, Habibi J, Wiedmeyer CE, Gallagher PE, Tallant EA, Cooper SA, Link CD, Ferrario C, Sowers JR 2006 Oxidative stress and glomerular filtration barrier injury: role of the renin-angiotensin system in the Ren2 transgenic rat. Am J Physiol Renal Physiol 291:F1308-F1314 (Pubitemid 44887244)
29. Kobori H, Katsurada A, Miyata K, Ohashi N, Satou R, Saito T, Hagiwara Y, Miyashita K, Navar LG 2008 Determination of plasma and urinary angiotensinogen levels in rodents by newly developed ELISA. Am J Physiol Renal Physiol 294:F1257-F1263
30. Maunsbach AB 1966 Observations on the segmentation of the proximal tubule in the rat kidney. J Ultrastruct Res 16:239-258
31. Nistala R, Whaley-Connell A, Sowers JR 2008 Redox control of renal function and hypertension. Antioxid Redox Signal 10:2047-2089
32. Alonso-Galicia M, Brands MW, Zappe DH, Hall JE 1996 Hypertension in obese Zucker rats. Role of angiotensin II and adrenergic activity. Hypertension 28:1047-1054
33. Gonzalez-Villalobos RA, Seth DM, Satou R, Horton H, Ohashi N, Miyata K, Katsurada A, Tran DV, Kobori H, Navar LG 2008 Intrarenal angiotensin II and angiotensinogen augmentation in chronic angiotensin II-infused mice. Am J Physiol Renal Physiol 295:F772-F779
34. Mundel P, Reiser J 2010 Proteinuria: an enzymatic disease of the podocyte? Kidney Int 77:571-580
35. Tojo A, Onozato ML, Kurihara H, Sakai T, Goto A, Fujita T 2003 Angiotensin II blockade restores albumin reabsorption in the proximal tubules of diabetic rats. Hypertens Res 26:413-419 (Pubitemid 36701683)
36. Tojo A, Onozato ML, Ha H, Kurihara H, Sakai T, Goto A, Fujita T, Endou H 2001 Reduced albumin reabsorption in the proximal tubule of early-stage diabetic rats. Histochem Cell Biol 116:269-276 (Pubitemid 32930140)
37. Nickolas TL, Barasch J, Devarajan P 2008 Biomarkers in acute and chronic kidney disease. Curr Opin Nephrol Hypertens 17:127-132 (Pubitemid 351253035)
38. Hayden MR, Chowdhury NA, Cooper SA, Whaley-Connell A, Habibi J, Witte L, Wiedmeyer C, Manrique CM, Lastra G, Ferrario C, Stump C, Sowers JR 2007 Proximal tubule microvilli remodeling and albuminuria in the Ren2 transgenic rat. Am J Physiol Renal Physiol 292:F861-F867 (Pubitemid 46220556)
39. Spahl DU, Berendji-Grün D, Suschek CV, Kolb-Bachofen V, Kröncke KD 2003 Regulation of zinc homeostasis by inducible NO synthase-derived NO: nuclear metallothionein translocation and intranuclear Zn2+ release. Proc Natl Acad Sci USA 100:13952-13957 (Pubitemid 37499172)
40. St. Croix CM, Wasserloos KJ, Dineley KE, Reynolds IJ, Levitan ES, Pitt BR 2002 Nitric oxide-induced changes in intracellular zinc homeostasis are mediated by metallothionein/thionein. Am J Physiol Lung Cell Mol Physiol 282:L185-L192 (Pubitemid 34654669)
41. Bakris GL, Fonseca V, Katholi RE, McGill JB, Messerli FH, Phillips RA, Raskin P, Wright Jr JT, Oakes R, Lukas MA, Anderson KM, Bell DS 2004 Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA 292:2227-2236 (Pubitemid 39473160)